Payers and targeted therapy in oncology
I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…